Skip to main content

Table 4 Mortality at 30 days and 365 days following admission in 57,110 adult ICU patients with and without pre-admission use of different drugs, according to atrial fibrillation status

From: Pre-existing atrial fibrillation and risk of arterial thromboembolism and death in intensive care unit patients: a population-based cohort study

 

Users, %

Non-users, %

Crude RRa

Adjusted RRa,b

30-day mortality

    

Statins

    

  No AF

15.8 (15.1–16.5)

16.1 (15.8–16.5)

0.98 (0.93–1.03)

0.83 (0.79–0.88)

  AF

23.6 (21.7–25.7)

28.4 (26.9–30.0)

0.83 (0.75–0.92)

0.93 (0.84–1.04)

Aspirin

    

  No AF

20.1 (19.3–20.8)

15.0 (14.7–15.4)

1.34 (1.28–1.40)

0.93 (0.88–0.97)

  AF

28.2 (26.3–30.3)

25.9 (24.4–27.5)

1.09 (0.99–1.20)

0.99 (0.91–1.09)

Vitamin K antagonists

    

  No AF

23.3 (21.1–25.7)

15.9 (15.5–1.62)

1.47 (1.33–1.62)

1.07 (0.97–1.19)

  AF

22.9 (21.3–24.6)

30.6 (28.9–32.4)

0.75 (0.68–0.82)

0.91 (0.82–1.00)

Beta-blockers

    

  No AF

17.2 (16.4–17.9)

15.8 (15.4–16.1)

1.09 (1.02–1.12)

0.91 (0.86–0.95)

  AF

26.4 (24.8–28.1)

27.3 (25.5–29.2)

0.97 (0.88–1.06)

1.07 (0.98–1.18)

Non-dihydropyridine CCBs

    

  No AF

21.4 (18.9–24.3)

16.0 (15.6–16.3)

1.34 (1.18–1.52)

1.04 (0.92–1.17)

  AF

24.2 (20.1–28.9)

27.0 (25.8–28.3)

0.90 (0.74–1.08)

0.86 (0.71–1.03)

Digoxin

    

  No AF

32.7 (29.6–36.2)

15.8 (15.5–16.1)

2.07 (1.87–2.30)

1.15 (1.03–1.28)

  AF

29.5 (27.4–31.8)

25.5 (24.0–27.0)

1.16 (1.05–1.27)

0.97 (0.88–1.07)

Amiodarone

    

  No AF

25.2 (18.3–34.2)

16.0 (15.7–16.3)

1.58 (1.15–2.16)

1.08 (0.83–1.42)

  AF

27.3 (23.0–32.2)

26.8 (25.5 -28.0)

1.02 (0.86–1.21)

1.15 (0.98 -1.34)

365-day mortality

    

Statins

    

  No AF

24.8 (24.0–25.6)

25.6 (25.1–26.0)

0.97 (0.94–1.01)

0.82 (0.79–0.86)

  AF

36.7 (34.5–39.1)

43.1 (41.4–44.8)

0.85 (0.79–0.92)

0.95 (0.88–1.02)

Aspirin

    

  No AF

31.0 (30.2–31.9)

23.9 (23.5–24.4)

1.30 (1.25–1.34)

0.93 (0.90–0.96)

  AF

42.7 (40.6–44.9)

39.8 (38.1–41.5)

1.07 (1.00–1.15)

1.00 (0.94–1.06)

Vitamin K antagonists

    

  No AF

37.8 (35.3–40.5)

25.1 (24.7–25.5)

1.51 (1.41–1.62)

1.11 (1.03–1.19)

  AF

35.4 (33.5–37.3)

46.3 (44.4–48.3)

0.76 (0.71–0.82)

0.91 (0.85–0.97)

Beta-blockers

    

  No AF

26.9 (26.0–27.7)

25.1 (24.6–25.5)

1.07 (1.03–1.11)

0.89 (0.86–0.93)

  AF

39.4 (37.6–41.3)

42.7 (40.7–44.8)

0.92 (0.86–0.99)

1.00 (0.95–1.07)

Non-dihydropyridine CCBs

    

  No AF

33.3 (30.3–36.5)

25.3 (24.8–25.6)

1.32 (1.20–1.45)

1.02 (0.94–1.11)

  AF

39.4 (34.6–44.7)

41.0 (39.6–42.4)

0.96 (0.84–1.10)

0.93 (0.82–1.05)

Digoxin

    

  No AF

50.1 (46.6–53.6)

25.0 (24.7–25.4)

2.00 (1.86–2.15)

1.16 (1.08–1.24)

  AF

45.0 (42.6 -47.4)

38.9 (37.3–40.6)

1.15 (1.08–1.24)

1.01 (0.95–1.08)

Amiodarone

    

  No AF

44.4 (35.8–53.9)

25.4 (25.0–25.7)

1.75 (1.42–2.15)

1.18 (0.99–1.41)

  AF

42.2 (37.3–47.4)

40.8 (39.4–42.2)

1.03 (0.91–1.17)

1.12 (1.01–1.25)

  1. AF atrial fibrillation, RR relative risk, CCBs calcium channel blockers
  2. 95% confidence intervals are given in parentheses
  3. aReference group was non-users within each stratum
  4. bAdjusted for age and sex, comorbidities, and consultations and services by the general practitioner